Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PIM1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Kinase | PIM1 Recombinant Protein / Mutants (wild-type and L120G gatekeeper mutant). High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Ideal for biochemical assays, selectivity screening, and resistance profiling. | View PIM1 Products |
| Resistance Mutant | PIM1 L120G (Gatekeeper) Mutant Protein. Validated for resistance screening, Theoretical MW confirmed, ATP-binding site intact. | View PIM1 Products |
| Gene Delivery | PIM1 Lentivirus Premade Particles. Full-length ORF for stable cell line construction, high titer (>10^8 TU/ml). Sequence verified. | View PIM1 Products |
| Benchmark Control | Anti-PIM1 Validated Antibodies. Recombinant positive control for western blot and immunohistochemistry. Sequence verified. | View PIM1 Products |
| Validator | PIM1 siRNA Set. For knockdown verification, sequence-specific >85% mRNA reduction. | View PIM1 Products |
| Family Member | PIM2 Kinase Domain Protein. For off-target selectivity screening and pan-PIM counter-screening. High homology comparator. | View PIM2 Products |
| Family Member | PIM3 Kinase Domain Protein. For comprehensive pan-PIM profiling and isoform specificity testing. | View PIM3 Products |
| Related Target | FLT3. Synergistic pathway in AML; combined inhibition circumvents resistance. Recombinant protein available. | View FLT3 Products |
Critical Assay Requirements & TarMart Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PIM1 vs PIM2/PIM3) | Human PIM1, PIM2, and PIM3 ortholog proteins available with >95% purity for strict counter-screening. Identical expression system (HEK293) for fair competition assays. |
| Drug Resistance Mutations | Gatekeeper (L120G) and activation loop mutants available; sequence verified by mass spec; critical for next-gen inhibitor design. |
| Kinase Activity Preservation | Insect/HEK293 expressed (native post-translational modifications) ensuring biologically relevant conformation. |
| ATP Competition Assay | High specific activity proteins with intact ATP-binding pockets; theoretical molecular weight confirmed by MS. |
| Cellular Target Validation | Validated siRNA and lentivirus included for specificity checks and overexpression studies. |
| Lack of Validated Knockdown Controls | Sequence-optimized siRNA sets included for robust cellular specificity checks. |
Live PIM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PIM1 therapeutics is intensifying, driven by its critical role in cell cycle regulation, apoptosis evasion, and resistance to standard chemotherapies in hematological malignancies (such as AML and multiple myeloma) and solid tumors (like prostate cancer). First-generation ATP-competitive small molecules face significant challenges from family redundancy (PIM2/PIM3 compensatory upregulation) and emerging gatekeeper mutations (e.g., L120G). Consequently, the field is rapidly shifting toward pan-PIM inhibitors, allosteric modulators, and PROTAC-mediated targeted protein degradation. Next-generation R&D is heavily focused on combination strategies with FLT3, PI3K, BCL-2, or CDK inhibitors to shut down parallel survival pathways and overcome resistance. As clinical data mature, the demand for high-purity recombinant proteins, including wild-type and mutant variants, as well as cell-based tools for degradation and selectivity assays, will continue to grow.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitors (ATP-competitive) | Incyte, Novartis, Astellas, AstraZeneca (AZD1208) | AML, Multiple Myeloma, Prostate Cancer | Selectivity Assay (Need high-purity PIM1, PIM2, PIM3 panel) |
| Pan-PIM Inhibitor | Ryvu Therapeutics (SEL24-BEN) | AML, CLL | Redundancy Bypass Validation (Need all three isoforms for combo studies) |
| PROTACs / Degraders | Arvinas, C4 Therapeutics | Refractory Hematological Malignancies, Solid Tumors | Cell-Based Degradation Assay (Need lentivirus for stable PIM1 expression) |
| Combination Therapies | Academic Consortia, Big Pharma, AbbVie (Venetoclax combos) | FLT3-mutated AML, Refractory AML | Synergy Validation (Need FLT3 and PIM1 recombinant proteins; validated siRNA for target validation) |